Introduction
============

Atherosclerosis is associated with several cardiovascular complications including myocardial infarction, coronary heart disease, cerebral infarction, diabetes and dyslipidemia ([@b1-etm-0-0-7717],[@b2-etm-0-0-7717]). It is a chronic inflammatory arterial disease causing serious medical and socioeconomic problems ([@b1-etm-0-0-7717],[@b2-etm-0-0-7717]). Chronic vascular inflammation plays an important and understudied role in the initiation, development and progression of atherosclerosis ([@b3-etm-0-0-7717],[@b4-etm-0-0-7717]). Vascular smooth muscle cells (VSMCs) are a dominant cellular constituent of arteries and play key roles in the development of atherosclerosis ([@b5-etm-0-0-7717],[@b6-etm-0-0-7717]). The inflammatory response to vascular injury promotes the dedifferentiation of VSMCs, which causes a switch of these cells from the quiescent 'contractile' phenotype to the 'proinflammatory' phenotype ([@b5-etm-0-0-7717]). The dedifferentiated cells release cytokines and cause upregulation of multiple inflammasome components, which in turn promotes chemotaxis of monocytes/macrophages, thus accelerating the process of atherogenesis ([@b7-etm-0-0-7717],[@b8-etm-0-0-7717]). Therefore, the investigation of the underlying molecular mechanism involved in the inflammation of VSMCs may be of potential scientific interest.

MicroRNAs (miR/miRNA) are small RNA molecules that contribute to mRNA degradation or transcriptional inhibition by direct interaction with the 3′-untranslated region (3′UTRs) of their target mRNAs. miRNAs regulate gene expression at the post-transcriptional level and have emerged as potential critical regulators of diverse biological and pathological processes ([@b9-etm-0-0-7717],[@b10-etm-0-0-7717]). Accumulating evidence has shown that miRNAs play an important role in the processes of atherogenesis ([@b11-etm-0-0-7717],[@b12-etm-0-0-7717]). For example, a recent study demonstrated that the expression levels of miR-20a were repressed in human aortic endothelial cells treated with oxidized LDL (ox-LDL), whereas the overexpression of miR-20a reduced the production of reactive oxygen species and the development of inflammatory injuries ([@b13-etm-0-0-7717]). A clinical trial conducted by Hao *et al* ([@b14-etm-0-0-7717]) indicated that miR-125a-5p levels were downregulated in atherosclerotic plaques of coronary atherosclerosis patients. Decreased expression of miR-125a-5p in patients with arteriosclerosis was also observed in another clinical trial ([@b6-etm-0-0-7717]). This evidence suggests that miR-125a-5p plays an important role in atherosclerosis. However, the underlying molecular mechanism of miR-125a-5p in the progression of atherosclerosis is still poorly understood.

The inflammasome of NACHT, LRR and PYD domains-containing protein 3 (NLRP3) is composed of NLRP3, apoptosis associated speck-like protein (ASC) and caspase-1. This complex triggers the conversion of pro-caspase-1 to active caspase-1. The active form of caspase-1 can convert the cytokine precursor pro-interleukin (IL)-1β into mature and biologically active IL-1β, which can trigger an inflammatory response ([@b15-etm-0-0-7717],[@b16-etm-0-0-7717]). The present study aimed to explore the role of miR-125a-5p in atherosclerosis and to identify novel targets that may be clinically useful. The data indicated that miR-125a-5p was significantly downregulated in ox-LDL-treated human VSMCs (HVSMCs). Overexpression of miR-20a negatively regulated NLRP3 inflammasome by targeting the C-C motif chemokine ligand 4 (CCL4) and resulted in the protection of HVSMCs from ox-LDL-induced inflammatory injury.

Materials and methods
=====================

### Cell culture and treatment

HVSMCs (American Type Culture collection; ATCC^®^ CRL-1999™) were cultured in Dulbecco\'s modified Eagle\'s medium (Invitrogen; Thermo Fisher Scientific, Inc.) supplemented with 10% fetal bovine serum (Invitrogen; Thermo Fisher Scientific, Inc.), in a humidified atmosphere with 5% CO~2~ at 37°C. The cells were treated with ox-LDL (20 µg/ml) for 24 h.

### Transfection

The cells were seeded in a six-well plate at a density of 4×10^5^ cells/ml for 24 h prior to transfection. The miR-125a-5p mimics (5′-UCCCUGAGACCCUUUAACCUGUGA-3′), the miR-125a-5p (5′-UCACAGGUUAAAGGGUCUCAGGGA-3′) inhibitor and the corresponding negative control \[NC (5′-UUGUACUACACAAAAGUACUG-3′)\] samples were synthesized by Shanghai GenePharma, Co., Ltd., and transfected into the VSMCs using Lipofectamine™ 2000 reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer\'s protocol. The final concentrations of miR-125a-5p mimics, NC mimics, miR-125a-5p inhibitor and NC inhibitor were 30, 30, 100 and 100 nM, respectively. The si-CCL4 (5′-GCCACAACCUGUCACUCAATT-3′, cat. no. stB0007785C-1-5; Guangzhou RiboBio, Co., Ltd.) and si-NC (5′-UUCUCCGAACGUGUCACGUUU-3′, cat. no. siN05815122147-1-5; Guangzhou RiboBio, Co., Ltd.) were transfected into the cells with a final concentration of 50 pM. Further experiments were performed at 48 h after transfection.

### Immunofluorescence

HVSMCs were seeded on coverslips at a density of 4×10^5^ cells per ml in a six-well plate for 24 h. At 24 h following ox-LDL treatment, the cells were fixed in 4% formaldehyde at 25°C for 15 min and blocked in 5% normal goat serum (Invitrogen; Thermo Fisher Scientific, Inc.)/0.3% Triton^™^ X-100 for 1 h at room temperature. The cells were incubated with anti-α-smooth muscle actin (cat. no. 34105; 1:50; Cell Signaling Technology, Inc.) antibody at 4°C overnight and subsequently with a fluorescein-conjugated mouse anti-rabbit IgG (cat. no. sc-2359; 1:500; Santa Cruz Biotechnology, Inc.) for 1 h at room temperature. Following staining with DAPI (D9542; Sigma-Aldrich; Merck KGaA) for 5 min at room temperature, the samples were imaged using a laser scanning confocal microscope (Leica Microsystems GmbH) at 200× magnification.

### ELISA

The culture medium of the ox-LDL-treated HVSMCs was collected. The levels of IL-1β were measured by IL-1β ELISA kits (cat. no. ab100562; Abcam) according to the manufacturer\'s protocols.

### Western blotting

Total proteins were extracted from cells using RIPA lysis buffer (Beyotime Institute of Biotechnology). The protein concentration was measured using the bicinchoninic acid kit (Bio-Rad Laboratories, Inc.). The protein samples (30 µg/lane) were separated on 10% SDS-PAGE gels and blotted onto polyvinylidene difluoride membranes (EMD Millipore Corp.). The membranes were blocked in 5% non-fat milk for 1 h at room temperature, followed by overnight incubation at 4°C with primary antibodies as follows: NLRP3 (cat. no. 13158; 1:1,000; Cell Signaling Technology, Inc.), ASC (cat. no. 13833; 1:1,000; Cell Signaling Technology, Inc.), caspase-1 (cat. no. 3866; 1:1,000; Cell Signaling Technology, Inc.), IL-1β (cat. no. 12703; 1:1,000; Cell Signaling Technology, Inc.), α-SMA (cat. no. 68463; 1:1,000; Cell Signaling Technology, Inc.), CCL4 (cat. no. ab106028; 1:1,000; Abcam) and GAPDH (cat. no. sc-81545; 1:2,000; Santa Cruz Biotechnology, Inc.), respectively. Then membranes were further probed with horse radish peroxidase-conjugated secondary antibody rabbit anti-mouse (1:10,000; cat. no. sc-358914; Santa Cruz Biotechnology, Inc.) or mouse anti-rabbit (1:10,000; cat. no. sc-2357; Santa Cruz Biotechnology, Inc.) at 4°C overnight and immunoblots were visualized using an ECL Plus chemiluminescence kit (Amersham Biosciences). The relative protein expression was analyzed using ImageJ software 1.4 (National Institute of Health).

### Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

Total RNA from cells was extracted using the TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) as described in the manufacturer\'s protocol. The TaqMan microRNA reverse transcription kit (Takara Bio, Inc.) combined with specific stem-loop primers and Prime Script^™^ RT reagent kit (Takara Biotechnology Co., Ltd.) were used to obtain cDNA from miR-125a-5p and mRNA molecules respectively, according to the manufacturer\'s protocol. Reaction conditions were as follows: 37°C for 15 min, followed by incubation at 85°C for 5 sec. RT-qPCR was performed using a Perfect Real Time SYBR Premix Ex Taq kit (Takara Bio, Inc.) with an ABI 7500 thermal cycler (Thermo Fisher Scientific, Inc.) under the following conditions: 95°C for 2 min, followed by 40 cycles of 95°C for 30 sec and 60°C for 30 sec. The experiments were repeated at least three times. Quantitative measurements were analyzed by the 2^−ΔΔCq^ method ([@b17-etm-0-0-7717]). The expression of *U6* and *GAPDH* was used as internal control for the expression of miRNA and mRNA molecules, respectively. The primers sequences used were the following: *NLRP3*, forward, 5′-GCGCCTCAGTTAGAGGATGT-3′, reverse: 5′-ACCAGCTACAAAAAGCATGGA-3′; *ASC*, forward: 5′-TGGATGCTCTGTACGGGAAG-3′, reverse: 5′-CCAGGCTGGTGTGAAACTGAA-3′; *caspase-1*, forward: 5′-TTTCCGCAAGGTTCGATTTTCA-3′, reverse: 5′-GGCATCTGCGCTCTACCATC-3′; *IL-1β*, forward: 5′-GGGCCTCAAGGAAAAGAATC-3′, reverse: 5′-TTCTGCTTGAGAGGTGCTGA-3′; *CCL4*, forward: 5′-GCTTTTCTTACACTGCGAGGA-3′, reverse: 5′-CCAGGATTCACTGGGATCAG-3′; *GAPDH*, forward:5′-AAGGTGAAGGTCGGAGTCAAC-3′, reverse: 5′-GGGGTCATTGATGGCAACAATA-3′; *U6*, stem-loop primer: 5′-GTCGTATCCAGTGCAGGGTCCGAGGTGCACTGGATACGACAAAATATGG-3′, forward: 5′-TGCGGGTGCTCGCTTCGGCAGC-3′ and reverse: 5′-CCAGTGCAGGGTCCGAGGT-3′. miR-125a-5p, stem-loop primer: 5′-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACTCACAG′, forward: 5′-AGCGCGTCCCTGAGACCCTTTAAC-3′ and reverse: 5′-CCAGTGCAGGGTCCGAGGT-3′.

### Dual-luciferase reporter assays

TargetScan Human ([www.targetscan.org](www.targetscan.org)) was used to predict that CCL4 is the potential target of miR-125a-5p. The mutant type of the CCL4 3′UTR sequence was constructed using a GeneArt™ Site-Directed Mutagenesis System (cat. no. A13282; Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer protocol. The wild type or mutant type of CCL4 3′UTR was then cloned into the firefly luciferase reporter vector with the pGL3-promoter (Promega Corp.) to generate the recombinant vector pGL3-CCL4-3′UTR wild type (3′UTR-WT) or pGL3-CCL4-3′UTR mutant type (3′UTR-MUT). 293T cells (ATCC) were cultured in 24 well plates for 24 h and co-transfected with 50 ng 3′UTR-WT (or 3′UTR-MUT) vector and 20 µM of miR-125a-5p (or NC) mimics. The transfections were performed using Lipofectamine™ 2000 reagent (Invitrogen; Thermo Fisher Scientific, Inc.) as indicated by the manufacturer\'s protocol. At 48 h following transfection, the Dual-Luciferase Reporter Assay System (Promega Corp.) and Turner DesignsTD-20/20 luminometer (Promega Corp.) were used to determine the luciferase activity normalized to *Renilla*.

### Statistical analysis

The data are presented as the mean ± standard deviation. The differences between two groups were analyzed using the Student\'s t-test. The comparisons among the multiple groups of data were analyzed by one-way analysis of variance followed by the Dunnett\'s post hoc test. P\<0.05 was considered to indicate a statistically significant difference. All data were analyzed using SPSS 13.0 software (SPSS, Inc.).

Results
=======

### Ox-LDL treatment increases NLRP3 expression and decreases miR-125a-5p expression levels in HVSMCs

The levels of the VSMC differentiation marker α-SMA were measured by immunofluorescence and western blot assays in order to observe the phenotypic alterations of HVSMCs induced by ox-LDL. The results indicated that ox-LDL significantly downregulated α-SMA expression (P\<0.01; [Fig. 1A and B](#f1-etm-0-0-7717){ref-type="fig"}). The production and release of the inflammatory mediators by VSMCs played a critical role in atherogenesis. The data suggested that ox-LDL treatment significantly increased NLRP3, ASC, caspase-1 and IL-1β expression levels (P\<0.01; [Fig. 1C and D](#f1-etm-0-0-7717){ref-type="fig"}). Furthermore, the results of the RT-qPCR assay indicated that the miR-125a-5p levels were significantly decreased in ox-LDL-treated HVSMCs (P\<0.01; [Fig. 1E](#f1-etm-0-0-7717){ref-type="fig"}).

### miR-125a-5p is responsible for the ox-LDL induced expression of NLRP3 and IL-1β

To identify the role of miR-125a-5p in the progression of atherosclerosis, miR-125a-5p mimics and miR-125a-5p inhibitor were used to cause upregulation and downregulation of miR-125a-5p expression levels, respectively, in ox-LDL-treated HVSMCs ([Figs. 2](#f2-etm-0-0-7717){ref-type="fig"} and [3](#f3-etm-0-0-7717){ref-type="fig"}). Overexpression of miR-125a-5p significantly inhibited the expression levels of NLRP3, ASC, caspase-1 and IL-1β in HVSMCs (P\<0.01; [Fig. 2B and C](#f2-etm-0-0-7717){ref-type="fig"}). In contrast to the miR-125a-5p mimics, the expression levels of NLRP3, ASC, caspase-1 and IL-1β were significantly increased in the miR-125a-5p inhibitor group compared with those noted in the NC group (P\<0.001; [Fig. 3B and C](#f3-etm-0-0-7717){ref-type="fig"}). The data suggested that miR-125a-5p is, at least partly, responsible for the induction of NLRP3 and IL-1β expression that was mediated by ox-LDL treatment.

### CCL4 is a direct target gene of miR-125a-5p

TargetScan Human 7.1 ([www.targetscan.org](www.targetscan.org)) was used to investigate whether *CCL4* is a potential target of miR-125a-5p. RT-qPCR and western blot assays were performed to detect the expression levels of CCL4 mRNA and protein, respectively, and the results indicated that overexpression of miR-125a-5p significantly decreased CCL4 expression levels (P\<0.01; [Fig. 2B and C](#f2-etm-0-0-7717){ref-type="fig"}), whereas downregulation of miR-125a-5p exhibited the opposite effects (P\<0.001; [Fig. 3B and C](#f3-etm-0-0-7717){ref-type="fig"}). Furthermore, a dual-luciferase reporter assay was performed. Transfection of miR-125a-5p mimics and the CCL4 3′UTR-WT vector significantly reduced luciferase activity compared with transfection of NC mimics and the CCL4 3′UTR-WT vector in HVSMCs (P\<0.01; [Fig. 4](#f4-etm-0-0-7717){ref-type="fig"}). However, no significant change was noted in the cells that were transfected with the CCL4 3′UTR-WT vector ([Fig. 4](#f4-etm-0-0-7717){ref-type="fig"}). The results indicated that miR-125a-5p could directly bind to the 3′UTR of CCL4.

### Knockdown of CCL4 attenuates miR-125a-5p inhibitor induced NLRP3 and IL-1β expression

In order to further explore the role of CCL4 in ox-LDL-induced HVSMCs, the cells were co-transfected with si-CCL4 or si-NC and the miR-125a-5p inhibitor ([Fig. 5](#f5-etm-0-0-7717){ref-type="fig"}). The results of the western blot assays indicated that the expression levels of CCL4 were significantly downregulated in HVSMCs transfected with si-CCL4 compared with those of the si-NC group (P\<0.001; [Fig. 5A](#f5-etm-0-0-7717){ref-type="fig"}). Moreover, silencing of *CCL4* significantly decreased the expression levels of NLRP3, ASC, caspase-1 and IL-1β in HVSMCs transfected with the miR-125a-5p inhibitor (P\<0.05; [Fig. 5C](#f5-etm-0-0-7717){ref-type="fig"}). These results demonstrated that knockdown of *CCL4* could attenuate activation of the NLRP3 inflammasome and the production of its downstream substrate IL-1β that was mediated by the inhibition of miR-125a-5p.

Discussion
==========

Ox-LDL can regulate the expression of inflammatory factors and enhance the cellular inflammatory response ([@b17-etm-0-0-7717],[@b18-etm-0-0-7717]). During that process, vascular damage is induced, which leads to the development of atherosclerosis ([@b18-etm-0-0-7717],[@b19-etm-0-0-7717]). Accumulating evidence has suggested that the inflammatory response to vascular injury promotes the dedifferentiation of VSMCs, which accelerates the process of atherogenesis ([@b3-etm-0-0-7717],[@b4-etm-0-0-7717]). In the present study, the data demonstrated that ox-LDL addition upregulated the expression levels of *α-SMA*, which is one of the VSMC differentiation marker genes. In addition, the expression of NLRP3 and its downstream gene *IL-1β* was upregulated in ox-LDL-treated HVSMCs. This result was consistent with the study by Li *et al* ([@b20-etm-0-0-7717]), which demonstrated that ox-LDL treatment increased the expression levels of NLRP3 and of its downstream genes (*caspase-1, IL-1β* and *IL-18*) in a dose-dependent manner. Inflammation plays a key role in the stages of atherogenesis. A variety of inflammatory cytokines have been associated with atherosclerosis, including IL-1β ([@b21-etm-0-0-7717]). IL-1β can promote the inflammatory response and enhance VSMC proliferation and migration ([@b22-etm-0-0-7717]). A recent randomized, placebo-controlled trial indicated that the monoclonal antibody canakinumab, which directly targets and neutralizes IL-1β, was associated with reduced risk of adverse cardiovascular events compared with that noted for the placebo subjects ([@b23-etm-0-0-7717]). In addition, the activation of the NLRP3 inflammasome is a powerful mediator of the inflammatory response that contributes to the VSMC phenotypic transformation and proliferation ([@b23-etm-0-0-7717]--[@b25-etm-0-0-7717]). It is therefore believed that the NLRP3 inflammasome activation is involved in the pathogenesis of atherosclerosis ([@b24-etm-0-0-7717]--[@b26-etm-0-0-7717]).

miR-125a-5p has been reported to be involved in numerous cellular functions by the regulation of multiple signaling pathways. For example, Natalia *et al* ([@b27-etm-0-0-7717]) suggested that miR-125a-5p promotes migration of cervical cancer cells via targeting the Microtubule-Affinity-Regulating Kinase1. In addition, overexpression of miR-125a-5p inhibits cell proliferation and migration by blocking the p38/JNK/ERK signaling pathway in salivary adenoid cystic carcinoma. In the present study, it was suggested that miR-125a-5p, which was downregulated following ox-LDL treatment, was responsible for the increased expression of NLRP3 and IL-1β in HVSMCs. Downregulation of miR-125a-5p in atherosclerotic patients was observed in previous studies ([@b6-etm-0-0-7717],[@b14-etm-0-0-7717]). However, these reports did not elucidate the underlying molecular pathways of miR-125a-5p that were involved in atherogenesis. In the current study, miR-125a-5p mimics and miR-125a-5p inhibitor were transfected into ox-LDL-treated HVSMCs in order to cause upregulation and downregulation of miR-125a-5p expression, respectively. The results demonstrated that miR-125a-5p may be involved in the process of the inflammatory response and in the development of atherogenesis by the regulation of the NLRP3 inflammasome. In addition, TargetScan Human ([www.targetscan.org](www.targetscan.org)) was used to predict whether *CCL4* is the potential target of miR-125a-5p. CCL4 is a member of the chemokine superfamily, which is rapidly induced following vascular damage. CCL4 is involved in the regulation of the inflammatory response ([@b28-etm-0-0-7717],[@b29-etm-0-0-7717]). The results of the dual-luciferase reporter assay suggested that *CCL4* is a direct target gene of miR-125a-5p. Furthermore, HVSMCs were co-transfected with si-CCL4 and the miR-125a-5p inhibitor. The knockdown of *CCL4* by siRNA attenuated the miR-125a-5p inhibitor-induced production of NLRP3 and IL-1β. Taken collectively, the results demonstrated that ox-LDL could induce NLRP3 and IL-1β expression by upregulating the expression levels of CCL4.

In conclusion, the current study suggested that ox-LDL treatment significantly downregulated miR-125a-5p levels and induced NLRP3, and IL-1β expression by upregulating the expression levels of the target gene of miR-125a-5p, CCL4. miR-125a-5p caused a negative regulation on the NLRP3 inflammasome by targeting CCL4 in ox-LDL treated HVSMCs. The data revealed that miR-125a-5p may be involved in the inflammatory response and the regulation of atherogenesis, indicating its potential application in atherosclerosis therapy.
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![Ox-LDL treatment increases and decreases NLRP3 and miR-125a-5p expression levels, respectively in HVSMCs. The cells were treated with ox-LDL (20 µg/ml) for 24 h. α-SMA levels was measured by (A) immunofluorescence and (B) western blot assays. The expression levels of (C) NLRP3, ASC, caspase-1 and (D) IL-1β were detected using western blotting and ELISA, respectively. (E) Reverse transcription quantitative-PCR assays were used to detect miR-125a-5p levels. Scale bar, 50 µm. \*\*P\<0.01 and \*\*\*P\<0.001 vs. HVSMCs. HVSMC, human vascular smooth muscle cells; miR, microRNA; IL, interleukin; ox-LDL, oxidised low-density lipoprotein; NLRP3, NACHT, LRR and PYD domains-containing protein 3; α-SMA, smooth muscle actin; ASC, apoptosis associated speck-like protein.](etm-18-03-1645-g00){#f1-etm-0-0-7717}

![Overexpression of miR-125a-5p inhibited the expression levels of NLRP3, ASC, caspase-1, IL-1β and CCL4 in HVSMCs. The cells were trasfected with miR-125a-5p mimics and NC mimics, and treated with ox-LDL treatment. (A) The miR-125a-5p levels were detected by RT-qPCR. (B) RT-qPCR and (C) western blot assays were performed to analyse the NLRP3, IL-1β and CCL4 mRNA and protein expression levels. \*\*P\<0.01 and \*\*\*P\<0.001 vs. ox-LDL + HVSMCs. HVSMC, human vascular smooth muscle cells; miR, microRNA; IL, interleukin; ox-LDL, oxidised low-density lipoprotein; NLRP3, NACHT, LRR and PYD domains-containing protein 3; α-SMA, smooth muscle actin; RT-q, reverse transcription-quantitative; CCL4, C-C motif chemokine 4-like; ASC, apoptosis associated speck-like protein.](etm-18-03-1645-g01){#f2-etm-0-0-7717}

![Downregulation of miR-125a-5p increases the expression levels of NLRP3, ASC, caspase-1, IL-1β and CCL4 in HVSMCs. The cells were trasfected with miR-125a-5p inhibitor and NC inhibitor, and treated with ox-LDL. (A) The miR-125a-5p levels were detected by RT-qPCR. (B) RT-qPCR and (C) western blot assays were performed to analyse NLRP3, ASC, caspase-1, IL-1β and CCL4 mRNA and protein expression levels. \*\*\*P\<0.001 vs. ox-LDL + HVSMCs. HVSMC, human vascular smooth muscle cells; miR, microRNA; IL, interleukin; ox-LDL, oxidised low-density lipoprotein; NLRP3, NACHT, LRR and PYD domains-containing protein 3; α-SMA, smooth muscle actin; RT-q, reverse transcription-quantitative; CCL4, C-C motif chemokine 4-like; NC, negative control; ASC, apoptosis associated speck-like protein.](etm-18-03-1645-g02){#f3-etm-0-0-7717}

![CCL4 is a direct target gene of miR-125a-5p. (A) The putative miR-125a-5p targeted sequences in the 3′-UTR of CCL4 mRNA are shown. (B) Dual-luciferase reporter assay was performed to analyse the relative luciferase activity in 293T cells. \*\*P\<0.01 vs. NC. CCL4, C-C motif chemokine 4-like; NC, negative control; miR, microRNA; UTR, untranslated region; WT, wild-type; Mut, mutant.](etm-18-03-1645-g03){#f4-etm-0-0-7717}

![Knockdown of *CCL4* attenuated the induction of NLRP3, ASC, caspase-1 and IL-1β expression by the miR-125a-5p inhibitor. human vascular smooth muscle cells were co-transfected with si-CCL4 and miR-125a-5p inhibitor for 48 h. (A) Western blot and (B) reverse transcription-quantitative PCR assays were performed to analyse CCL4 mRNA and protein expression levels. (C) The NLRP3, ASC, caspase-1 and IL-1β expression levels were detected by western blot assays. \*P\<0.05, \*\*P\<0.01 and \*\*\*P\<0.001 vs. miR-125a-5p inhibitor. CCL4, C-C motif chemokine 4-like; NC, negative control; IL, interleukin; miR, microRNA; si, small interfering; NLRP3, NACHT, LRR and PYD domains-containing protein 3; ASC, apoptosis associated speck-like protein.](etm-18-03-1645-g04){#f5-etm-0-0-7717}
